gr 144053 has been researched along with piperidines in 19 studies
| Studies (gr 144053) | Trials (gr 144053) | Recent Studies (post-2010) (gr 144053) | Studies (piperidines) | Trials (piperidines) | Recent Studies (post-2010) (piperidines) |
|---|---|---|---|---|---|
| 21 | 1 | 2 | 40,235 | 5,221 | 14,545 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (42.11) | 18.2507 |
| 2000's | 9 (47.37) | 29.6817 |
| 2010's | 2 (10.53) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Eldred, CD; Evans, B; Hindley, S; Judkins, BD; Kelly, HA; Kitchin, J; Lumley, P; Porter, B; Ross, BC; Smith, KJ | 1 |
| Heptinstall, S; Lösche, W; Sanderson, HM; Vickers, J | 1 |
| Coller, BS; Lang, D; Scudder, LE | 1 |
| Hayashi, H; Kaida, T; Kozawa, O; Matsuno, H; Niwa, M; Uematsu, T | 1 |
| Hayashi, H; Ito, T; Kozawa, O; Matsuno, H; Nishida, M; Niwa, M; Tanabe, K; Uematsu, T | 1 |
| Heptinstall, S; Storey, RF; Wilcox, RG | 1 |
| Ito, T; Kozawa, O; Matsuno, H; Niwa, M; Sakai, N; Uematsu, T | 1 |
| Kanamaru, M; Kozawa, O; Matsuno, H; Nagashima, S; Uematsu, T | 1 |
| Collen, D; Kozawa, O; Matsuno, H; Matsuo, O; Uematsu, T; Ueshima, S | 1 |
| Achison, M; Barnes, MJ; Elton, CM; Farndale, RW; Hargreaves, PG; Knight, CG | 1 |
| Collen, D; Kozawa, O; Matsuno, H; Matsuo, O; Nishida, M; Uematsu, T; Ueshima, S | 1 |
| Boncler, M; Golanski, J; Rozalski, M; Watala, C | 1 |
| Kozawa, O; Matsuno, H; Matsuo, O; Okada, K; Uematsu, T; Ueshima, S | 1 |
| Rozalski, M; Watala, C | 1 |
| Essex, DW; Farndale, RW; Griffiths, D; Hamaia, SW; Hess, O; Knight, CG; Lahav, J; Makris, M; Wijnen, EM | 1 |
| Ishisaki, A; Kitajima, Y; Kozawa, O; Matsuno, H; Tokuda, H; Zhou, Y | 1 |
| Cooley, BC; Isogai, N; Kusada, A | 1 |
| Diamond, SL; Herbig, BA | 1 |
| Bai, J; Fernández, JÁ; Griffin, JH; Lamb, JA; Lei, IF; Leung, J; Lyden, PD; Pereira, BR; Rajput, PS | 1 |
1 trial(s) available for gr 144053 and piperidines
| Article | Year |
|---|---|
Differential effects of glycoprotein IIb/IIIa antagonists on platelet microaggregate and macroaggregate formation and effect of anticoagulant on antagonist potency. Implications for assay methodology and comparison of different antagonists.
Topics: Adenosine Diphosphate; Anticoagulants; Citrates; Collagen; Eptifibatide; Hirudins; Humans; Nephelometry and Turbidimetry; Oligopeptides; Peptides; Peptides, Cyclic; Piperazines; Piperidines; Platelet Aggregation Inhibitors; Platelet Count; Platelet Glycoprotein GPIIb-IIIa Complex; Sodium Citrate; Thiazolidines | 1998 |
18 other study(ies) available for gr 144053 and piperidines
| Article | Year |
|---|---|
Orally active non-peptide fibrinogen receptor (GpIIb/IIIa) antagonists: identification of 4-[4-[4-(aminoiminomethyl)phenyl]-1-piperazinyl]-1-piperidineacetic acid as a long-acting, broad-spectrum antithrombotic agent.
Topics: Administration, Oral; Animals; Blood Platelets; Callithrix; Fibrinolytic Agents; Humans; Piperazines; Piperidines; Platelet Aggregation Inhibitors; Platelet Membrane Glycoproteins; Structure-Activity Relationship | 1994 |
Studies on the effects of agonists and antagonists on platelet shape change and platelet aggregation in whole blood.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Adenosine Diphosphate; Adenosine Triphosphate; Azepines; Blood Platelets; Humans; In Vitro Techniques; Piperazines; Piperidines; Platelet Activating Factor; Platelet Aggregation; Platelet Aggregation Inhibitors; Prostaglandin Endoperoxides, Synthetic; Serotonin; Succinates; Sulfonamides; Thromboxane A2; Triazoles; Vasoconstrictor Agents | 1996 |
Rapid and simple platelet function assay to assess glycoprotein IIb/IIIa receptor blockade.
Topics: Abciximab; Analysis of Variance; Animals; Antibodies, Monoclonal; Hemagglutination; Humans; Immunoglobulin Fab Fragments; In Vitro Techniques; Mice; Observer Variation; Oligopeptides; Piperazines; Piperidines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Recombinant Fusion Proteins; Reference Values; Thrombasthenia | 1997 |
GR144053, a fibrinogen receptor antagonist, enhances the suppression of neointima formation by losartan, an angiotensin II receptor antagonist, in the injured carotid artery of hamster.
Topics: Angiotensin Receptor Antagonists; Animals; Carotid Arteries; Cell Division; Cricetinae; Drug Administration Schedule; Drug Synergism; Losartan; Male; Piperazines; Piperidines; Platelet Glycoprotein GPIIb-IIIa Complex | 1997 |
Effect of GR144053, a fibrinogen-receptor antagonist, on thrombus formation and vascular patency after thrombolysis by tPA in the injured carotid artery of the hamster.
Topics: Animals; Bleeding Time; Carotid Artery Thrombosis; Cell Division; Cricetinae; Disease Models, Animal; Drug Interactions; Fibrinogen; Fibrinolytic Agents; Male; Muscle, Smooth; Peptides; Piperazines; Piperidines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombolytic Therapy; Tissue Plasminogen Activator; Vascular Patency | 1998 |
Comparison of the antithrombotic effects and bleeding risk of fractionated aurin tricarboxylic acid and the GPIIb/IIIa antagonist GR144053 in a hamster model of stenosis.
Topics: Animals; Aurintricarboxylic Acid; Carotid Stenosis; Catheterization; Cricetinae; Endothelium, Vascular; Hemorrhage; Infusions, Intravenous; Male; Mesocricetus; Piperazines; Piperidines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex | 1999 |
Comparative antiplatelet effects of aspirin, vapiprost and GR144053, a GPIIb/IIIa antagonist, with a special reference to the role of platelet microaggregates.
Topics: Animals; Aspirin; Biphenyl Compounds; Cricetinae; Fibrinolytic Agents; Heptanoic Acids; Male; Piperazines; Piperidines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombosis | 1999 |
Lack of tPA significantly affects antithrombotic therapy by a GPIIb/IIIa antagonist, but not by a thrombin inhibitor in mice.
Topics: Animals; Arginine; Bleeding Time; Carotid Artery Thrombosis; Dose-Response Relationship, Drug; Fibrinolytic Agents; Mice; Mice, Knockout; Pipecolic Acids; Piperazines; Piperidines; Platelet Glycoprotein GPIIb-IIIa Complex; Sulfonamides; Thrombin; Thrombolytic Therapy; Tissue Plasminogen Activator; Urokinase-Type Plasminogen Activator | 2000 |
Integrin-independent tyrosine phosphorylation of p125(fak) in human platelets stimulated by collagen.
Topics: Adult; Animals; Blood Platelets; Calcium; Cattle; Collagen; Egtazic Acid; Focal Adhesion Kinase 1; Focal Adhesion Protein-Tyrosine Kinases; Humans; Indoles; Integrins; Ionomycin; Ligands; Peptide Fragments; Phosphorylation; Piperazines; Piperidines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Precipitin Tests; Protein Kinase C; Protein-Tyrosine Kinases; Tyrosine | 2001 |
tPA, but not uPA, significantly affects antithrombotic therapy by a glycoprotein IIb/IIIa antagonist, but not by a factor Xa inhibitor.
Topics: Animals; Bleeding Time; Factor Xa Inhibitors; Fibrinolytic Agents; Indicators and Reagents; Mice; Naphthalenes; Partial Thromboplastin Time; Piperazines; Piperidines; Plasminogen Activators; Platelet Aggregation; Platelet Glycoprotein GPIIb-IIIa Complex; Propionates; Tissue Plasminogen Activator; Urokinase-Type Plasminogen Activator | 2000 |
Effects of fibrinogen receptor antagonist GR144053F and aurintricarboxylic acid on platelet activation and degranulation.
Topics: Adenosine Diphosphate; Adult; Aurintricarboxylic Acid; Cell Degranulation; Collagen Type I; Female; Flow Cytometry; Hemostasis; Humans; Male; Middle Aged; Piperazines; Piperidines; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex | 2001 |
Inhibitors of fibrinolytic components play different roles in the formation and removal of arterial thrombus in mice.
Topics: alpha-2-Antiplasmin; Animals; Arginine; Bleeding Time; Blood Coagulation; Carotid Artery Injuries; Endothelium, Vascular; Mice; Mice, Inbred C57BL; Mice, Knockout; Pipecolic Acids; Piperazines; Piperidines; Plasminogen Activator Inhibitor 1; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Serine Proteinase Inhibitors; Sulfonamides; Thrombin; Thrombin Time; Thrombosis; Vascular Patency | 2002 |
Antagonists of platelet fibrinogen receptor are less effective in carriers of Pl(A2) polymorphism of beta(3) integrin.
Topics: Adult; Eptifibatide; Female; Genotype; Humans; Integrin beta3; Intercellular Signaling Peptides and Proteins; Male; Nephelometry and Turbidimetry; Peptides; Piperazines; Piperidines; Platelet Aggregation; Platelet Glycoprotein GPIIb-IIIa Complex; Polymorphism, Genetic; Receptors, Fibrinogen | 2002 |
Enzymatically catalyzed disulfide exchange is required for platelet adhesion to collagen via integrin alpha2beta1.
Topics: 4-Chloromercuribenzenesulfonate; Anti-Bacterial Agents; Antibodies; Bacitracin; Carrier Proteins; Catalysis; Collagen; Cross-Linking Reagents; Disulfides; Dithionitrobenzoic Acid; Dose-Response Relationship, Drug; Humans; Integrin alpha2beta1; Ligands; Peptides; Piperazines; Piperidines; Platelet Adhesiveness; Platelet Glycoprotein GPIIb-IIIa Complex; Platelet Membrane Glycoproteins; Protein Binding; Protein Disulfide-Isomerases; Protein Structure, Tertiary; Recombinant Proteins; Sulfhydryl Compounds; Sulfhydryl Reagents | 2003 |
P2Y12 receptors play a significant role in the development of platelet microaggregation in patients with diabetes.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Aged; Diabetes Mellitus, Type 2; Female; Humans; Male; Membrane Proteins; Middle Aged; Piperazines; Piperidines; Platelet Aggregation; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Reference Values | 2005 |
Electric injury model of murine arterial thrombosis.
Topics: Animals; Carotid Arteries; Disease Models, Animal; Electric Injuries; Heparin; Kinetics; Mice; Piperazines; Piperidines; Platelet Aggregation; Thrombosis; Video Recording | 2007 |
Pathological von Willebrand factor fibers resist tissue plasminogen activator and ADAMTS13 while promoting the contact pathway and shear-induced platelet activation.
Topics: ADAM Proteins; ADAMTS13 Protein; Biopolymers; Blood Coagulation; Elastic Modulus; Fibrinolysin; Hemorheology; Humans; In Vitro Techniques; Lab-On-A-Chip Devices; P-Selectin; Piperazines; Piperidines; Platelet Activation; Platelet Adhesiveness; Platelet Glycoprotein GPIIb-IIIa Complex; Protein Subunits; Solubility; Tissue Plasminogen Activator; von Willebrand Factor | 2015 |
Neuroprotection and vasculoprotection using genetically targeted protease-ligands.
Topics: Animals; Anticoagulants; Brain; Brain Ischemia; Infarction, Middle Cerebral Artery; Ligands; Male; Neurons; Neuroprotection; Neuroprotective Agents; Piperazines; Piperidines; Protein C; Rats; Rats, Sprague-Dawley; Receptor, PAR-1; Receptors, Proteinase-Activated; Stroke; Thrombin | 2019 |